Patients and Methods Patients with previously treated NSCLC and adequate organ function regardless of EGFR mutation status were eligible for the phase I study, with wild-type EGFR were eligible for the phase II study. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.